explore -WSS

explore

author：focus 2025-09-29 20:50:58 - browse：537

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Patients' immediate access to test results puts radiologists in a bind

WSS

Pfizer plans to depart BIO

Chemotherapy shortages won’t get better under Biden’s latest plan

Medical device lobby: We're tired of waiting on Medicare coverage

AI models in health care face new federal disclosure requirements

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

hotspot

explore

focus

Wildfire smoke exposes gaps in outdoor worker protections

What causes an itch? Researchers may have solved the mystery

Bright Health sells Medicare Advantage business to Molina

Clinical trials giant ICON acquires HumanFirst

Psychedelics group wrestles with new pharma identity

What PEPFAR has meant on the ground in Ukraine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

AI models in health care face new federal disclosure requirements

Peter Hotez and the public health issue of online harassment

RaDonda Vaught to speak at CommonSpirit event on patient safety

hotspot

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

CMS should re

Patients' immediate access to test results puts radiologists in a bind

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Patients' immediate access to test results puts radiologists in a bind

Pharma patents targeted by Biden in move to slash drug prices

explore

leisure time

hotspot

focus